

23<sup>rd</sup> July, 2024

The Dy. General Manager (Listing Dept.) BSE Limited, Corporate Relationship Dept., 1st Floor, New Trading Ring, P. J. Towers, Dalal Street, Fort, Mumbai - 400 001

(BSE Scrip Code: 500420)

The Manager – Listing Dept., National Stock Exchange of India Ltd., Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G. Block, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051 (NSE Scrip Code: TORNTPHARM)

Dear Sir,

## Sub.: Presentation to analysts on unaudited Consolidated Financial Results for the quarter ended 30<sup>th</sup> June, 2024

The presentation on unaudited Consolidated Financial Results for the quarter ended 30<sup>th</sup> June, 2024 to be made to analysts is enclosed for your records.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI COMPANY SECRETARY

Encl: A/a

\_\_\_\_\_



Q1 FY 2024-25

Revenues: Summary



## **Revenue: Summary**

Revenues (Rs cr)	Q1 FY25	Q1 FY24	Gr%
India	1,635	1,426	15%
United States	259	293	-12%
Germany	284	258	10%
Brazil	196	190	3%
Others	485	424	14%
Total	2,859	2,591	10%

